Why is the Polynovo share price rocketing 17%?

Could more insider buying be behind Polynovo's Tuesday gains?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Polynovo share price launched 21.5% to its intraday high of $1.13 on Tuesday
  • Its gain came amid more news of insider buying at the company after an entity owned by its chair forked out $227,500 on-market yesterday
  • The surge is bad news for short-sellers targeting Polynovo with the company one of the most shorted on the ASX 

The Polynovo Ltd (ASX: PNV) share price is taking off on Tuesday despite the broader market's downturn.

At the time of writing, the Polynovo share price is $1.09, 17.2% higher than its previous close. Additionally, the medical device company's chair has snapped up another parcel of Polynovo shares.

For context, the All Ordinaries Index (ASX: XAO) and the S&P/ASX 200 Index (ASX: XJO) are both down around 1.3% right now. That marks a slight recovery after the indexes both hit a three-month low this morning.

Let's take a closer look at what might be going on with the Polynovo share price today.

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.

Image source: Getty Images

What's going on with Polynovo today?

The Polynovo share price is surging 17% today amid more news of insider buying.

An entity owned by the company's chair David Williams splashed out yesterday, snapping up $227,500 worth of Polynovo stock on the market.

The purchase saw the entity taking home 250,000 shares at a cost of 91 cents apiece. Thus, they're already bringing a 19.8% return on investment.

That – and the 1.5 million shares Williams purchased last week – has brought his holding in the company to 20.65 million shares.

Additionally, another two of the company's directors reported buying into its stock last week, each snapping up parcels of 100,000 shares.

That might suggest insiders believe the Polynovo share price recently bottomed out.

Today's gains see the medical device company's stock surpassing $1 for the first time in nearly two months. That's a win for investors, but it might be disappointing news for those shorting the stock.

The most recent data available shows 10% of Polynovo shares are in the hands of short-sellers, making it the fifth most shorted stock on the ASX, according to The Motley Fool Australia's latest weekly short-selling breakdown.

Polynovo share price snapshot

Despite today's surge, Polynovo's shares are still trading for 29% less than what they were at the start of 2022.

They have also fallen 60% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

CSL earnings: FY26 sees reset and path to future growth

The biotech giant has released its eagerly anticipated results this morning.

Read more »

A man looking at his laptop and thinking.
Earnings Results

Cochlear posts FY26 profit at top end of guidance with new product momentum

Management is guiding to a profit rebound in FY 2027.

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »